Stock Forecast Chart
Stock Price Prediction Summary
Forecast Score Based on 2 Weeks
Based on our forecast, the price of NURPF will - over the next 2 Weeks and hit - by . In that time frame, NURPF's share price is expected to range between - and -.
BearishAverageBullishNURPF shares fell -4.93% in Friday, December 19, 2025's trading session, dropping from a previous close of $12.89 to move at $12.25. The stock demonstrated notable intraday movement (see NURPF's key stats for a full breakdown), fluctuating between $12.25 and $12.25, a 0 trading range. While recent weeks have seen some volatility, NURPF has managed to secure a -6.42% drop over the past 2 weeks. The downward price movement was accompanied by decreased trading volume, with approximately 100 shares changing hands, 2.8K fewer than the previous session. This amounted to $1.23K in total market activity.
Will NURPF Continue Its Trend?
According to analyst ratings and projections for NURPF, Neuren Pharmaceuticals Limited shares are anticipated to remain stable by -, potentially reaching - per share by January 1, 1970. Short-term technical indicators for NURPF currently suggest a bearish sentiment. This aligns with the stock's recent performance, as it has recorded 18 negative trading days within the past 30 sessions. Based on the NURPF stock forecast, now is not the best time to buy NURPF stock because its current trading price is - our predicted value, hinting at a possible . For deeper insights, view our sentiment analysis on NURPF covering social and institutional perspectives.
NURPF Technical Momentum: Overbought, Oversold, or Neutral?
An analysis of Relative Strength Index (RSI) indicators provides insight into NURPF's momentum. Short-term RSIs (9, 14, and 20-day figures ranging from 36.40% to 46.01%) suggest mixed signals, with the stock in a neutral to slightly bearish momentum phase. The 50-day RSI, at 50.81%, suggests a neutral medium-term outlook. Additionally, the 100-day RSI, at 52.68%, maintains a neutral outlook for the long term. Insights into NURPF's shareholder base show how institutional investors are positioning themselves during these momentum shifts

